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Case Report

Thrombotic Thrombocytopenic Purpura
Induced by Acute Pancreatitis
Socrates G. Roedan, MD;1* Nihar N. Shah, MD;2 Robert Spira, MD1
2
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Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small
blood vessels of the body (microthrombi), resulting in a low platelet count. The disease consists of the
pentad of microangiopathic hemolytic anemia, thrombocytopenic purpura, neurologic abnormalities, fever
and renal disease. Many symptoms could develop with acute pancreatitis but being able to differentiate
when it is associated with any hematological conditions such as TTP is crucial to initiate a proper medical
treatment. We present a rare case of a thirty-eight years old African American female, who presented to
the Emergency department with an abdominal pain associated with a pancreatic condition. A vital piece in
medical practice is recognizing lifesaving decisions in critical conditions cases. Acute Pancreatitis (AP) is a
well-described consequence of TTP but acute pancreatitis triggering TTP is still not as frequent.
[N A J Med Sci. 2016;9(2):75-77. DOI: 10.7156/najms.2016.0902075]
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INTRODUCTION
The annual incidence of Thrombotic thrombocytopenic
purpura (TTP) is approximately three cases per one million
adults per year, which makes the disease not as frequent as
other conditions.1 At least a minimum of two diagnostic
criteria are required to make the diagnosis, one of them being
microangiopathic hemolytic anemia (MAHA) and
thrombocytopenia, which may be accompanied by central
nervous system, renal, gastrointestinal and cardiac
involvement.2 The decisive cause of TTP is not well known,
but one of the etiologies described by the investigators is the
deficiency or dysfunction of A Disintegrin and
Metalloproteinase with a Thrombospondin type 1 motif
Member 13 (ADAMTS13) leading to accumulation of ultralarge von Willebrand factor molecules; and subsequent von
Willebrand
factor (vWF)/platelet-rich microvascular
thrombosis.3 Most of the time TTP in adults is idiopathic;
however in our case TTP may be secondary. 4
During acute pancreatitis, pancreatic tissue damage is a result
of intracellular activation of enzymes that lead to an
inflammatory response and release of cytokines. 5
TTP as a consequence of acute pancreatitis continues to be
rare.
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CASE REPORT
This is a 38 yrs. old African American female who was
admitted to the hospital with abdominal pain of 5 days after
binge alcohol abuse. Pain was mainly on the epigastrium
with severe intensity, radiating to the left flank, left upper
back and associated with nausea and vomiting.
Patient’s medical history is significant for HIV since 2008
with latest CD4 of 169/13%, alcohol abuse and two episodes
of pancreatitis in the past. Laboratory findings during this
admission showed an elevated amylase of 2000 U/L (N < 115
U/L), lipase 800 U/L (N < 190 U/L). Her urea 28 mg/dl and
creatinine 1.29 mg/dl. Total bilirubin 1.2 mg/dl, direct
bilirubin 0.7 mg/dl, aspartate aminotransferase (AST) was 65
IU/L, alanine aminotransferase 27 IU/L, blood glucose of 88
ng/dl, albumin 2.9 g/dl and lactate dehydrogenase (LDH) was
68 IU/L. Her white blood count was elevated to 8000 mcL.
Hematocrit was 26.8 %, with hemoglobin of 8.6 g/dL and
platelets were 10 x 103/mm3. Latest platelets count on our
medical record system before this admission was of 292 x
103/mm3 on September 21st, 2013 (patient did not have blood
work done since then). Ultrasound abdomen showed no
gallstones and enlarged pancreas, reflecting underlying
pancreatitis. Computed tomography of abdomen also showed
mild pancreatic inflammation with no gallbladder stone and
small pericardial fluid. Patient was diagnosed as acute
pancreatitis secondary to alcohol use.
Patient was immediately evaluated by the medical intensive
care unit (MICU) for severe thrombocytopenia in acute
pancreatitis and was started on intravenous fluids as part of
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her medical treatment. Patient received a total of 3 liters of
normal saline divided in between bolus and continuous
infusions with input and output well documented as per
MICU protocol.
 Second blood set showed elevated amylase of 579 U/L,
lipase of 1362 U/L, platelets 10,000 x 103/mm3; Hct
20.4%, Hgb 6.7 g/dl. Urea and creatinine remained stable
but LDH rose up to 319 associated with peripheral smear
showing significant schistocytes of 4%. Reticulocytes
count 6.9 % with fibrinogen levels and the coagulation
profile normal. ADAMTS 13 enzyme assay test was less
than 10%. Based on the abnormal labs values, patient was
diagnosed with TTP with evident MAHA and elevated
creatinine level compared to patient baseline. All signs
and symptoms on this patient, plus thrombocytopenia and
mild renal impairment favor TTP rather than HUS as our
diagnosis. Patient had pan CT scan with negative results
performed in order to rule out any possible malignancy as
associated triggering factor for TTP in a patient with HIV.
She was already on HAART therapy with a CD4 count
more than 150 cells/mm3 and without evidence of any
opportunistic infections.
Plasmapheresis on this patient was started in addition to
Methylprednisolone, which is a well-established TTP
treatment.
Patient received three plasmapheresis sessions as an inpatient
with an evident improvement of platelet counts, urea and
creatinine along with hemoglobin level. Patient’s hospital
course took an unexpected turn when she on her 11th day of
admission signed out against medical advice returning within
24 hrs. of leaving. During re-admission blood work remained
stable with Hg 10 g/dl1, HCT 30.2%, persistent low platelets
of 31,000 x 10/mm3, WBC 15 cells/mm3, AST 45 IU/L, ALT
45 IU/L, Alkaline Phosphatase 68 U/L and bilirubin 1.9
mg/dl. Abdominal CT scan was not repeated this time. As
her medical treatment was reinstated, the recovery course
was complicated resulting in altered mental status from her
second session of plasma exchange post re-admission with
normal EEG and CT head as a part of her neurological
evaluation. Patient’s baseline mental status recovered 3 days
post corticosteroids dose adjustment and four more session of
plasmapheresis given. Patient was discharged on the 7th day
of second admission with a follow up appointment scheduled
within a month after discharge from hospital. Patient was
stable with normal platelet count and anemia resolved.
DISCUSSION
TTP by itself is a well-known life-threatening condition and
could be deadly if it is present during acute pancreatitis.
MAHA and thrombocytopenia characterized TTP as a result
of microvascular platelet clumping most of the time
associated with ischemic organ dysfunction as neurological
signs and renal insufficiency.
In all published TTP cases, less than 12% shows a
recognized triggering factor for this condition. Well known

North American Journal of Medicine and Science

causes of secondary TTP are pregnancy, cancer, bone
marrow transplantation and certain drugs such as
clopidogrel.6 In this case, TTP association in between HIV
and acute pancreatitis could trigger the question: which was
the main starting point for TTP to develop?7 Recently, TTP
has also been associated with Human immunodeficiency
virus (HIV) infected patients with CD4 count less than
100/microliters. Nevertheless, in the great majority of cases,
TTP usually develops even without any triggering condition.
Severe deficiency of ADAMTS13 has been present on most
idiopathic cases, which prevent to process unusually large
vWF multimers released from endothelial cells. Formations
of microvascular thrombus may be part of the consequences.
In adults, the main result of severe ADAMTS13 deficiency is
often caused by ADAMTS13 auto antibodies. Plasma
exchange with replacement of fresh frozen plasma remains as
treatment of choice on all patients with acute TTP.
The evidence of immunological component on the course of
the disease as auto-antibodies against ADAMTS13 in a
relevant number of patients; provides the rationale for the use
of corticosteroids along with plasmapheresis as part of the
medical management.
Pancreatic manifestation is common in TTP; evidence of this
is revealed on post mortem cases by Hosler et al. in their
study, where they found pancreatic involvement in 30 out of
51 cases diagnosed with TTP. The mechanism for pancreatic
injury during TTP is thought to be due to impairment of
pancreatic circulation by thrombus occlusion of small vessels;
resulting in ischemia.8
On the other hand, as reported by Swisher et al. during the
revision of 16 cases in which the acute inflammatory
response present during acute pancreatitis triggered the onset
of TTP on five of them with a median of three days. It has
been demonstrated in in-vitro studies that inflammatory
cytokines stimulated endothelial cell release of ultra large
vWF multimers and inhibited the cleavage of ultra large vWF
ADAMTS13.
Prompt treatment with available effective options is
imperative, which makes it vital to recognize this disease
early in relation with acute pancreatitis.
Our case is another example of what Swisher et al. reported
during the series case evaluation, which revealed the short
interval in between the first sign of acute pancreatitis and the
subsequent TTP manifestations.
CONCLUSION
As acute pancreatitis incidence tends to increase, it is
important to recognize its association with TTP; despite the
presence of any other possible factors. A high clinical
suspicion and detailed physical examination is necessary for
an early diagnosis an initiation of plasma exchange therapy
remains as a lifesaving option.9,10

North American Journal of Medicine and Science

Apr 2016 Vol 9 No.2
2.

ACKNOWLEDGMENT
This case report was self-supported.
3.
FUNDING RESOURCE DISCLOSURE
No funds needed for this case report.
CONFLICT OF INTEREST
The authors have no conflict of interest to disclose.

4.

ABBREVIATIONS
TTP, Thrombotic thrombocytopenic purpura; HUS, Hemolytic uremic
Syndrome; AP, Acute pancreatitis; MAHA, Microangiopathic hemolytic
anemia; vWF, von Willebrand factor.

5.
6.
7.

REFERENCES
1.
Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and
adults with thrombotic thrombocytopenic purpura associated with
severe, acquired Adamts13 deficiency: comparison of incidence,
demographic and clinical features. Pediatr Blood Cancer. 2013;
60:1676-1682.

8.
9.

10.

77

Scully M, Yarranton H, Liesner R, et al. Regional UK TTP Registry:
Correlation with laboratory ADAMTS 13 analysis and clinical features.
Br J Haematol. 2008;142:819-826.
Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in
thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:
Relation to presenting features and clinical outcomes in a prospective
cohort of 142 patients. Blood. 2003;102:60-68.
Varadarajulu S, Ramsey WH, Israel RH, et al. Thrombotic
thrombocytopenic purpura in acute pancreatitis. J Clin Gastroenterol.
2000;31:243-245.
Gullo L, Cavichhi L, Tomassetti P, et al. Effects of ischemia on the
human pancreas. Gastroenterology. 1996;111:1033-1038.
Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and
related disorders. Hematol Oncol Clin North Am. 1990;4:219-241.
Leaf AN, Laubenstein LJ, Raphael B, et al. Thrombotic
thrombocytopenic purpura associated with human immunodeficiency
virus type Iinfection. Ann Intern Med. 1988;109:194-197.
Gullo L, Cavichhi L, Tomassetti P, et al. Effects of ischemia on the
human pancreas. Gastroenterology. 1996;111:1033-1038.
Shepard KV, Bukowski RM. The treatment of thrombotic
thrombocytopenic purpura with exchange transfusion, plasma infusion,
and plasma exchange. Semin Hematol. 1987;24:178-186.
Gillis S. The thrombocytopenic purpuras: Recognition and
management. Drugs. 1996;51:942-953.

